Casein kinase 2 mRNA transcripts (CK2 mRNA) (CK2 mRNA)

Casein kinase 2 (CK2) mRNA transcripts are the messenger RNA molecules that encode the subunits of the CK2 enzyme, a highly conserved and constitutively active serine/threonine kinase. The CK2 holoenzyme typically exists as a heterotetramer composed of two catalytic subunits (alpha and/or alpha-prime) and two regulatory beta subunits (1.1.1, 1.5.1). These mRNA transcripts are considered therapeutic targets for RNA-based modalities, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which aim to downregulate CK2 protein expression (1.4.1, 1.4.2). CK2 is frequently overexpressed in various malignancies, including leukemias and solid tumors, where it promotes cell survival, proliferation, and resistance to apoptosis by modulating pathways like PI3K/Akt/mTOR and NF-kappaB (1.1.1, 1.2.4). While most clinical-stage drugs like Silmitasertib (CX-4945) target the CK2 protein's ATP-binding site, targeting the mRNA transcripts provides an alternative strategy to deplete the enzyme's cellular pool and overcome potential resistance mechanisms (1.3.2, 1.4.1). Experimental studies have shown that silencing CK2 mRNA can effectively induce apoptosis in cancer cells and sensitize them to chemotherapy (1.4.2).

Other names

CSNK2A1 mRNACSNK2A2 mRNACSNK2B mRNACasein kinase II mRNACK2 alpha mRNACK2 beta mRNA

RNA interference (RNAi) and antisense-mediated degradation of mRNA transcripts to reduce protein expression levels.